Industry Pharmaceutical Founded 1989 | Traded as NASDAQ: VCEL Products CarticelEpicelMACI Number of locations 3 | |
 | ||
Formerly called Aastrom Biosciences, Inc. Key people Nick Colangelo (CEO)Daniel Orlando (COO)Gerard Michel (CFO)Ross Tubo (CSO)Dave Recker (CMO) Stock price VCEL (NASDAQ) US$ 2.80 0.00 (0.00%)31 Mar, 4:00 PM GMT-4 - Disclaimer Headquarters Ann Arbor, Michigan, United States Subsidiaries Genzyme Biosurgery ApS, Zellera AG, Aastrom Biosciences, Sl | ||
Vericel corporation
Vericel Corporation is a public, American biopharmaceutical company which was known prior to October 2014 as Aastrom Bio. Vericel is a commercial stage company with three marketed drugs. The company's research focus is on cell-based therapies.
Contents
- Vericel corporation
- Vericel corp vcel stock chart technical analysis for 12 14 16
- History
- Corporate governance
- Operations
- Products
- In development
- References
Vericel corp vcel stock chart technical analysis for 12 14 16
History
Aastrom Bio was formed in 1989 in Ann Arbor, Michigan.
In the spring of 2013, Aastrom Bio acquired from Sanofi the "cell therapy and regenerative medicine business" which it had received when purchasing Genzyme in 2011. This transformed the company in several ways: it increased the employee count by 8-fold and provided a revenue stream and products to market (which it had not had before).
In October 2014, the company changed its name from Aastrom Bio to Vericel and relocated its headquarters from Ann Arbor, Michigan to Cambridge, Massachusetts.
Corporate governance
As of November 2014, Vericel's chief executive officer (CEO) was Nick Colangelo. The company has had at least two prior CEOs; Daniel Orlando, who held this role as of January 2013, and Tim Mayleben, who resigned in October 2012. Daniel Orlando was a former vice president for business development across North and South America at Takeda. Orlando stayed with Vericel and, as of November 2014, was the company's chief operating officer (COO).
As of November 2014, the chief financial officer (CFO) role was held by Gerard Michel.
As of November 2014, the chief medical officer was Dave Recker.
As of November 2014, Vericel's chief science officer role had been filled by Ross Tubo.
Among those outside the C-suite, Brian Gibson held the position of vice president for finance as of January 2013.
Operations
Vericel has at least two facilities: an R&D facility in Ann Arbor, Michigan and a manufacturing facility in Cambridge, Massachusetts. There is a manufacturing capability in Ann Arbor, though, which includes manufacture of ixmyelocel-T. There was also a facility in Denmark which focused on MACI production; however, as of November 2014, there was a drive to close this facility and pick up manufacture at the Cambridge manufacturing site.
As of November 2014, the sales force dedicated to Carticel was 23 people, while there were only three people dedicated to Epicel sales.
Products
Vericel has three products: Carticel, Epicel and MACI.
There tends to be an uptick in Epicel use during the winter as a consequence of "inappropriate or unfortunate accidental use of heating elements".
In development
In 2013, Vericel had ixmyelocel-T undergoing clinical trials for two indications: critical limb ischaemia and ischaemic dilated cardiomyopathy.